Abstract:Antiangiogenic therapy is considered to be a promising strategy for the treatment of cancers. VEGF and its receptors are important angiogenic factors involved in tumor growth. In the present study, the new ruthenium(ii) complexes containing 2,6-bis(benzimidazolyl)pyridine have been identified as potent antiangiogenic agents in vitro and in vivo, through activation of distinct antiangiogenic signaling pathways. Specifically, [Ru(bbp)(p-mpip)Cl]ClO4 (complex , bbp = 2,6-bis(benzimidazolyl)pyridine; p-mpip = 2-(4-methylphenyl)imidazo[4,5-f]-1,10-phenanthroline) exhibited the highest antiangiogenic activity, as evidenced by significant suppression of neovessel formation in chick chorioallantoic membranes and blockage of the angiogenesis in a matrigel plugs assay, which are significantly higher than those of the most accepted anti-metastasis ruthenium-based drug NAMI-A. Generally, these kinds of complexes induced the G0/G1cell cycle by inhibiting the formation of a Cyclin D1/CDK4 complex and CDK2 activation, through up regulation of the expression levels of p15(INK4B), p21(Cip1) and p27(Kip1). Moreover, the complexes also triggered intracellular DNA damage, and thus activated the phosphorylation of ATM, ATR, CHK1, Histone and p53. The suppression of Akt and ERK1/2 pathways reinforced the cell cycle perturbation effects of the complexes. Interestingly, complex displayed strong inhibition on the activation of VEGF and VEGFR-2 phosphorylation, which blocked the transmission of the mitogenic signal through Akt and ERK1/2 pathways, and thus enhanced cell cycle arrest. In contrast, we found that the most accepted anti-metastasis ruthenium based drug NAMI-A exerted lower antiangiogenic activity via activation of the DNA damage-mediated pathway, but showed no effects on VEGF and VEGFR-2 phosphorylation. Taken together, this study clearly demonstrates the distinct antiangiogenic mechanisms of metal complexes, and these kinds of complexes can be further developed as anti-vascularized drugs and as alternative agents of NAMI-A for the treatment of cancers.

Antiangiogenic Ruthenium(ii) Benzimidazole Complexes, Structure-Based Activation of Distinct Signaling Pathways

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Antimetastatic activity of (arene)ruthenium(II) complex of 4-aryl-4H-naphthopyran

Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

Anti-metastasis and anti-proliferation effect of mitochondria-accumulating ruthenium(II) complexes via redox homeostasis disturbance and energy depletion

Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.

Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity Through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.

Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.

Novel Ruthenium Complexes Ligated with 4-Anilinoquinazoline Derivatives: Synthesis, Characterisation and Preliminary Evaluation of Biological Activity.

Unlocking the Potential of Iridium and Ruthenium Arene Complexes As Anti-Tumor and Anti-Metastasis Chemotherapeutic Agents.

Ruthenium Complexes with Phenylterpyridine Derivatives Target Cell Membrane and Trigger Death Receptors-Mediated Apoptosis in Cancer Cells.

Ruthenium complexes with ABIRATERONE acetate as ANTIPROLIFERATIVE agents

Cytotoxic Cis-Ruthenium(iii) Bis(amidine) Complexes.

A Novel Ruthenium(ii)-Polypyridyl Complex Inhibits Cell Proliferation and Induces Cell Apoptosis by Impairing DNA Damage Repair.

Potential Anticancer Agent for Selective Damage to Mitochondria or Lysosomes: Naphthalimide-modified Fluorescent Biomarker Half-Sandwich Iridium (III) and Ruthenium (II) Complexes

Ruthenium(II) Polypyridyl Complexes with Visible Light-Enhanced Anticancer Activity and Multimodal Cell Imaging.

Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives

Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.